Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00612274 · ClinicalTrials.gov registry record · Early Phase 1
Sirolimus, Tacrolimus and Short Course Methotrexate for Prevention of Acute GVHD in Recipients of Mismatched Unrelated Donor Allogeneic Stem Cell Transplantation
A Early Phase 1 study of Stem Cell Transplantation, sponsored by Yale University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT00612274 is a Early Phase 1 study of Stem Cell Transplantation that has completed, run by Yale University. The registered enrollment target is 26 participants, below the 42-participant average among 8 other Stem Cell Transplantation trials with a reported enrollment target (38% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00612274, a Early Phase 1 study of Stem Cell Transplantation, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this trial is to study the safety and efficacy of a novel regimen of sirolimus, tacrolimus and methotrexate as prophylaxis against acute graft versus host disease (GVHD) in recipients of mismatched unrelated donor stem cell grafts. Methotrexate is administered in a low dose format of 5mg/m2 on days +1,3 and 6 only.
Conditions Studied
Interventions
- DRUG Sirolimus
- DRUG Methotrexate
- DRUG tacrolimus
Study Locations (1)
Connecticut
- Yale University School of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2007-10 |
| Est. Completion | 2014-10 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00612274
The ClinicalTrials.gov registry entry for NCT00612274 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 42-participant average among 8 other Stem Cell Transplantation trials with a reported enrollment target (38% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Stem Cell Transplantation appearing as the primary indexed condition, and to 3 interventions - of which Sirolimus is the first listed.
NCT00612274 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT00612274 about?
NCT00612274 is a clinical study titled "Sirolimus, Tacrolimus and Short Course Methotrexate for Prevention of Acute GVHD in Recipients of Mismatched Unrelated Donor Allogeneic Stem Cell Transplantation". The primary objective of this trial is to study the safety and efficacy of a novel regimen of sirolimus, tacrolimus and methotrexate as prophylaxis against acute graft versus host disease (GVHD) in recipients of mismatched unrelated donor stem cell grafts. Methotrexate is administered in a low dose ...
What is the current status of trial NCT00612274?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 26 participants. The study started on 2007-10. Estimated completion is 2014-10.
What conditions does trial NCT00612274 study?
This clinical trial studies the following conditions: Stem Cell Transplantation.
What interventions are being tested in trial NCT00612274?
The interventions under investigation include: Sirolimus (DRUG), Methotrexate (DRUG), tacrolimus (DRUG).
Who is sponsoring clinical trial NCT00612274?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00612274 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stem Cell Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation
ACTIVE NOT RECRUITING · NA
-
Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure
ACTIVE NOT RECRUITING · Phase 2
-
Feasibility Neurocognitive Outcome After Transplant
ACTIVE NOT RECRUITING · NA
-
C-Reactive Protein as a Predictor of Stem Cell Transplant Complications
COMPLETED
-
Post-HSCT Medication Adherence mHealth App
COMPLETED
-
The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study (The POSEIDON-Pilot Study)
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.